Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2

Authors

  • Nigel J. M. Birdsall Francis Crick Institute
  • Sophie Bradley University of Leicester https://orcid.org/0000-0002-0035-4090
  • David A. Brown University College London
  • Noel J. Buckley King's College London
  • R.A. John Challiss University of Leicester
  • Arthur Christopoulos Monash University https://orcid.org/0000-0003-4442-3294
  • Richard M. Eglen PerkinElmer
  • Frederick Ehlert University of California Irvine
  • Christian C. Felder Lilly Research Laboratories
  • Rudolf Hammer Nippon Boehringer Ingleheim
  • Heinz J. Kilbinger University of Mainz
  • Günter Lambrecht University of Frankfurt
  • Chris Langmead Monash University
  • Fred Mitchelson University of Melbourne
  • Ernst Mutschler University of Frankfurt
  • Neil M. Nathanson University of Washington
  • Roy D. Schwarz Pfizer
  • David Thal Monash University https://orcid.org/0000-0002-0325-2524
  • Andrew B. Tobin University of Leicester https://orcid.org/0000-0002-1807-3123
  • Celine Valant Monash University https://orcid.org/0000-0002-2509-7465
  • Jurgen Wess National Institutes of Health

DOI:

https://doi.org/10.2218/gtopdb/F2/2021.2

Abstract

Muscarinic acetylcholine receptors (mAChRs) (nomenclature as agreed by the NC-IUPHAR Subcommittee on Muscarinic Acetylcholine Receptors [50]) are activated by the endogenous agonist acetylcholine. All five (M1-M5) mAChRs are ubiquitously expressed in the human body and are therefore attractive targets for many disorders. Functionally, M1, M3, and M5 mAChRs preferentially couple to Gq/11 proteins, whilst M2 and M4 mAChRs predominantly couple to Gi/o proteins. Both agonists and antagonists of mAChRs are clinically approved drugs, including pilocarpine for the treatment of elevated intra-ocular pressure and glaucoma, and atropine for the treatment of bradycardia and poisoning by muscarinic agents such as organophosphates. I

Published

25-Jun-2021

Issue

Section

Summaries

How to Cite

“Acetylcholine receptors (muscarinic) in GtoPdb v.2021.2” (2021) IUPHAR/BPS Guide to Pharmacology CITE, 2021(2). doi:10.2218/gtopdb/F2/2021.2.